A network meta-analysis compared vibegron, mirabegron and tolterodine for overactive bladder. Only five studies met inclusion criteria, with 5,317 patients contributing to the primary outcome.
Vibegron ranked best for reduction in urgency episodes, urge urinary incontinence episodes and maximum voided volume per void. Mirabegron ranked best for reduction in urinary frequency over 24 hours. So the two beta-3 agonists separated on which symptom they addressed rather than on overall superiority.
On adverse events the picture is muddier, and the authors say so plainly. Any adverse event was most frequent with vibegron, and constipation specifically. Tolterodine had the highest rates of hypertension and dry mouth. But definitions of adverse events varied between studies and reporting was inconsistent, so these comparisons are much weaker than the efficacy ones.
Five studies is a thin network for three drugs. The finding worth carrying is the symptom-specific split — that the choice may reasonably follow which symptom troubles the patient most — rather than any ranking of the drugs overall.
- Let the dominant symptom guide the choice: urgency and incontinence favour vibegron, frequency favours mirabegron.
- Tolterodine carried the highest dry mouth and hypertension rates here, though reporting was inconsistent.
- Constipation was most frequent with vibegron — worth asking about at review.
- Five studies is a thin evidence base; treat the rankings as provisional.
- The analysis does not account for contraindications, cost or availability, which usually decide the prescription.
The statistics, in plain English
This is a network meta-analysis, which infers comparisons between drugs never tested head to head by connecting them through shared comparators. That works when the trials enrolled similar patients and used similar outcomes, and misleads when they did not. Five studies across three drugs is a sparse network, so several of these comparisons rest on a single trial. The adverse event comparisons deserve much less weight than the efficacy ones for a reason the authors state: without standardised definitions, a drug studied by teams who recorded symptoms more thoroughly will look worse than one studied by teams who did not.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free